GLP-1

Sales & Marketing

Coming soon: The Life Sciences Industry Report 2025 – insigh...

Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends

News

Wegovy romps ahead after key rival sees slowdown

Novo Nordisk's sales of blockbuster obesity drug Wegovy grew by a massive 79% in the third quarter, in a relief to investors after disappointing results three months ago.

News

Representation of Ascendis Pharma technology

Novo puts $285m into monthly GLP-1 based on Ascendis tech

Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist.

News

Slide showing non-alcoholic fatty liver disease (NAFLD)

Novo Nordisk will file semaglutide for MASH next year

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US

News

Novo joins Lilly in asking FDA for ban on GLP-1 compounding

Novo Nordisk has asked the FDA to stop compounding pharmacies making cheaper versions of its semaglutide-based therapies for obesity and diabetes, saying the drug is too complex to be made

News

FDA rethinking block on compounding of Lilly's obesity drug

The FDA has said it has agreed to reconsider its decision to prevent compounding pharmacies from producing and selling versions of Eli Lilly's diabetes and obesity drug tirzepatide.

Coming soon: The Life Sciences Industry Report 2025 – insigh...

Wegovy romps ahead after key rival sees slowdown

Novo puts $285m into monthly GLP-1 based on Ascendis tech

Novo Nordisk will file semaglutide for MASH next year

Novo joins Lilly in asking FDA for ban on GLP-1 compounding

FDA rethinking block on compounding of Lilly's obesity drug

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

GLP-1

Editor's Picks